FDA Approves Unknown Drug — DIFGEN PHARMS

# FDA Approves DIFGEN Pharms Generic Drug Application DIFGEN Pharms has received FDA approval for its abbreviated new drug application (ANDA 219997), potentially expanding the company's generic drug portfolio and positioning it to capture market share in an established therapeutic category. The approval could provide DIFGEN with near-term revenue opportunities as it brings a bioequivalent alternative to market, subject to patent and exclusivity considerations.